Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer

被引：41
作者：
Barrio, Martin [1 ]
Fendler, Wolfgang P. [1 ,2 ]
Czernin, Johannes [1 ]
Herrmann, Ken [1 ,3 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[2] Ludwig Maximilians Univ Munchen, Dept Nucl Med, Munich, Germany
[3] Univ Hosp Essen, Dept Nucl Med, Essen, Germany
来源：
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2016年 / 16卷 / 11期
关键词：
PET; PSMA; Gallium; Lutetium; prostate cancer; therapy; theranostic; POSITRON-EMISSION-TOMOGRAPHY; RADIOLIGAND THERAPY; C-11-CHOLINE PET/CT; BIOCHEMICAL RELAPSE; RADIATION-DOSIMETRY; RADICAL PROSTATECTOMY; BONE-SCINTIGRAPHY; RADIONUCLIDE THERAPY; RECURRENCE; BIODISTRIBUTION;
D O I：
10.1080/14737159.2016.1243057
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Introduction: Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either Ga-68 for positron-emission-tomography (PET) or Lu-177 for radionuclide therapy.Areas covered: In this literature review we evaluate the diagnostic value of Ga-68 PSMA PET/CT and the therapeutic potential of Lu-177 PSMA radioligand therapy (RLT) in patients with prostate cancer. Ga-68 PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management. The preliminary data for Lu-177 PSMA indicates >50% reduction of PSA levels in up to 59% of patients. Severe adverse events occurred <10% of patients after RLT.Expert commentary: PSMA ligands for diagnostic and therapeutic purpose will significantly impact the management of patients with prostate cancer.
引用
收藏
页码：1177 / 1188
页数：12
相关论文
共 102 条
[1]   Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience [J].
Afshar-Oromieh, A. ;
Haberkorn, U. ;
Schlemmer, H. P. ;
Fenchel, M. ;
Eder, M. ;
Eisenhut, M. ;
Hadaschik, B. A. ;
Kopp-Schneider, A. ;
Roethke, M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) :887-897
[2]   PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].
Afshar-Oromieh, A. ;
Malcher, A. ;
Eder, M. ;
Eisenhut, M. ;
Linhart, H. G. ;
Hadaschik, B. A. ;
Holland-Letz, T. ;
Giesel, F. L. ;
Kratochwil, C. ;
Haufe, S. ;
Haberkorn, U. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495
[3]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[4]   Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].
Afshar-Oromieh, Ali ;
Zechmann, Christian M. ;
Malcher, Anna ;
Eder, Matthias ;
Eisenhut, Michael ;
Linhart, Heinz G. ;
Holland-Letz, Tim ;
Hadaschik, Boris A. ;
Giesel, Frederik L. ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20
[5]   Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [J].
Ahmadzadehfar, Hojjat ;
Eppard, Elisabeth ;
Kuerpig, Stefan ;
Fimmers, Rolf ;
Yordanova, Anna ;
Schlenkhoff, Carl Diedrich ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Essler, Markus .
ONCOTARGET, 2016, 7 (11) :12477-12488
[6]   Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Kuerpig, Stefan ;
Boegemann, Martin ;
Claesener, Michael ;
Eppard, Elisabeth ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Schaefers, Michael ;
Essler, Markus .
EJNMMI RESEARCH, 2015, 5 :1-8
[7]   Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued rise of biochemical failure after 5 years [J].
Amling, CL ;
Blute, ML ;
Bergstralh, EJ ;
Seay, TM ;
Slezak, J ;
Zincke, H .
JOURNAL OF UROLOGY, 2000, 164 (01) :101-105
[8]  
[Anonymous], CNM
[9]  
[Anonymous], 2016, CNM
[10]   177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].
Baum, Richard P. ;
Kulkarni, Harshad R. ;
Schuchardt, Christiane ;
Singh, Aviral ;
Wirtz, Martina ;
Wiessalla, Stefan ;
Schottelius, Margret ;
Mueller, Dirk ;
Klette, Ingo ;
Wester, Hans-Juergen .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013
12345678910